Cell Robotics Reports On Annual Shareholders' Meeting.

Business Editors/Health Writers

ALBUQUERQUE, N.M.--(BW HealthWire)--May 23, 2000

Cell Robotics International (OTCBB:CRII), the developer of the Lasette(R), a laser finger perforator that allows diabetics to draw blood in a nearly painless manner as the first step in obtaining a blood sample to test glucose levels, held its 2000 Annual Meeting of Shareholders at the Albuquerque Hilton on Friday, May 19.

At the meeting, the four incumbent members of the board of directors, Dr. Ronald K. Lohrding, Mark Waller, Dr. Raymond Radosevich and Dr. Debra Bryant, were reelected. In addition, Andrew F. Pollet, Dipl. Ing. Oton Tisch and Steven A. Crees have been elected to serve for the ensuing year and until their successors are elected.

Longtime Board Member Craig Rogers has decided to step down as director of the company to pursue other professional interests. Rogers will continue to participate in an occasional advisory role.

Newly Elected Board Members

Andrew F. Pollet is the managing principal of Pollet & Richardson, a law corporation, which he founded in 1983. Pollet's primary concentration is securities law and general corporate law. Pollet serves as a director of several corporations including STAAR Surgical Company, Jordan Pharmaceuticals Inc., Page Digital Inc. and San Joaquin Chemicals.

Pollet also sits on the board of directors for Sherwood Country Club in Westlake Village, Calif. Pollet received his Juris Doctor degree from the University of San Diego School of Law in 1977 and was admitted to the California bar in that same year. Pollet received his bachelor of science and MBA degrees from the University of Southern California in 1973 and 1974, respectively.

Steven Crees has previously served as an advisor to the board. He recently resigned as senior vice president and general manager of the Medical Diagnostic Products Division of Chronimed Inc., where he has been since the early 1990s.

Most recently, he was responsible for planning and implementation of distribution strategies for proprietary and licensed medical products into the hospital, long term care, physician, alternative care and retail markets for this $32 million business unit with a large focus on the diabetic market.

While still at Chronimed, he served as vice president for Marketing and Sales and managed the diabetes centers. Previous to that, he was territory manager for the Medical Products Division of Baxter Healthcare Corp. He has a bachelor of science degree in economics and business administration from the University of Minnesota.

Dipl. Ing. Oton Tisch was appointed to the board in February of 2000. Tisch is an international businessman who is the president, CEO and sole owner of Obras Electromecanicas TKV, Caracas, Venezuela, and its subsidiary in Zurich, Switzerland, which was incorporated 1980.

The company specializes in equipment procurement, building and financing high voltage turn-key substations up to 400 kV, including the electronic and/or digital automatic control. From 1957 to 1978, Tisch served first at the Siemens Schuckertwerke, Germany, and later as technical director and member of the board at Siemens S.A. Caracas, and from 1979-80, he served as an advisor.

Commenting on the appointment of the new board members, Lohrding stated: "We are pleased to expand the depth and breadth of expertise of our board of directors. Mr. Pollet, Mr. Crees and Mr. Tisch each bring invaluable perspectives to our board from their respective backgrounds, and we look forward to their participation in the next phase of our company's growth."

Shareholders also ratified the appointment of KPMG LLP as independent accountants of the company for its fiscal year ending Dec. 31, 2000, and passed an amendment to the articles of incorporation to increase the authorized common stock to 50 million shares.

Although the proposal to amend the company's 1992 Incentive Stock Option Plan was favored by the shareholders voting on this issue, it failed to pass because of a lack of a quorum of voting shareholders.

In his presentation updating shareholders on company operations, Lohrding commented: "We are pleased to report that we have resolved the issues in connection with the manufacture of the Personal Lasette. The weeks of May 8th and May 15th, we manufactured approximately 35 and 50 Lasettes, respectively.

"We are now initiating a marketing and advertising push aimed at gaining recognition of the Lasette as the best, most practical and comfortable way for diabetics to ensure more complete ongoing disease management and a better quality of life. We will have more to say in the near future on the quality of distributors available to us as we are increasing production.

"We are also pleased that the shareholders ratified the proposed increase in the number of authorized shares in Cell Robotics, which will give us flexibility in taking advantage of market and strategic opportunities as they arise."

About Cell Robotics International Inc.

Cell Robotics International Inc. (www.cellrobotics.com) is a multi-product medical devices company transitioning from the development phase of a unique and important FDA-approved laser-based device to production and sales in a large and growing market for diabetic patient products and services. The company conducts operations in two product categories: laser-based medical devices and scientific research instruments.

Forward-looking statements (statements that are not historical fact) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including the following: changes in economic conditions, general competitive factors, the company's ability to execute its manufacturing, service and product sales plans and uncertainties detailed in the company's filings with the Securities and Exchange Commission.